Lundbeck has potential name for migraine drug: Vyepti

Lundbeck's billion-dollar migraine drug based on eptinezumab will possibly be marketed under the name Vyepti, providing the US health authorities approve the drug later this month.

Photo: Jens Dresling/Politiken/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles